The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.
Ja Yoon HeoChanghee ParkBhumsuk KeamChan-Young OckMiso KimTae Min KimDong-Wan KimSe Hyun KimYu Jung KimJong Seok LeeDae Seog HeoPublished in: Thoracic cancer (2019)
Despite high PD-L1-positive rates, ICIs show limited efficacy in ALK-positive NSCLC. Decreased interferon-γ-related response may underlie these findings.